Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 07, 2016 2:09 AM ET

Healthcare Equipment and Supplies

Company Overview of Zyomyx, Inc.

Company Overview

Zyomyx, Inc. engages in the development and commercialization of diagnostic platforms. The company offers disposable CD4 T-cell, a point-of-care test for HIV/AIDS treatment. Zyomyx, Inc. also provides a platform technology for cell counting. The company was founded in 1998 and is based in Fremont, California.

6519 Dumbarton Circle

Fremont, CA 94555

United States

Founded in 1998





Key Executives for Zyomyx, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 50
Director of Technology
Director of Finance and Administration
Compensation as of Fiscal Year 2015.

Zyomyx, Inc. Key Developments

Zyomyx, Inc. Receives $7.5 Million from UNITAID to Commercialize its Quantitative MyT4 Point-of-Care CD4 Test

Zyomyx, Inc. has been awarded $7.5 million from UNITAID to commercialize its quantitative MyT4(TM) point-of-care CD4 test, designed to guide HIV/AIDS treatment initiation and monitoring in low- and middle-income countries. UNITAID's funding contribution is part of its strategy to speed up access to a range of new and improved technologies from a number of manufacturers for HIV/AIDS, tuberculosis and malaria for the world's most vulnerable populations. It will support field evaluations of the product, training for national HIV programs, and country-level and global regulatory filings. The Zyomyx test is the fastest point-of-care CD4 diagnostic on the market and delivers results that are equivalent to lab-based flow cytometry, the gold standard of CD4 testing. The MyT4(TM) CD4 test is commercially available receiving a CE Mark in December 2013.

Similar Private Companies By Industry

Company Name Region
Lumed Science Inc. United States
LightWave Ablation Systems, Inc. United States
Bisco, Inc. United States
Trifoil Imaging Inc. United States
The Implantology Group United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Zyomyx, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at